Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Stage I Prostate Adenocarcinoma 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Raloxifene Hydrochloride × Genitourinary × Clear all
NCT00710970 2022-01-24

Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment

Baylor College of Medicine

Phase 2 Completed
28 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms

NCT03147196 2019-01-22

Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Mayo Clinic

Phase 2 Withdrawn
Genitourinary

Stage I Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡